On this page:Overview Publications Researchers Institutions Open access

ScholarIQanswers from OpenAlex

Eternity Bioscience (United States)

InstitutionResearch output, impact & collaborations

Eternity Bioscience (United States) is a institution indexed in ScholarIQ from OpenAlex.

What is known about Eternity Bioscience (United States)?

ScholarIQrecord summary

Eternity Bioscience (United States) is a research organisation in Cranbury, US. OpenAlex records 227 works and 7,447 citations for it. 64 researchers list it as their most recent affiliation.

How many works does Eternity Bioscience (United States) have?

ScholarIQindexed works

Eternity Bioscience (United States) has 227 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

See the works listed for Eternity Bioscience (United States) →

How many citations does Eternity Bioscience (United States) have?

ScholarIQcitation count

Eternity Bioscience (United States) has 7,447 citations in the OpenAlex counts ScholarIQ stores.

See the listed works for Eternity Bioscience (United States) →

How many researchers are at Eternity Bioscience (United States)?

ScholarIQresearcher count

Eternity Bioscience (United States) has 64 researchers in the ScholarIQ index.

See the researchers listed on this page →

What is the average h-index at Eternity Bioscience (United States)?

ScholarIQavg h-index

Eternity Bioscience (United States) has an average h-index of 30 in OpenAlex.

Open the OpenAlex record →

What is the ROR of Eternity Bioscience (United States)?

ScholarIQror

The ROR for Eternity Bioscience (United States) is on the source record.

Open the ROR →

What is the OpenAlex record for Eternity Bioscience (United States)?

ScholarIQopenalex

The OpenAlex for Eternity Bioscience (United States) is on the source record.

Open the OpenAlex →

Who are the most-cited researchers behind Eternity Bioscience (United States)?

ScholarIQtop researchers by citations

Jonathan D. Schwartz · Hepatocellular Carcinoma Treatment and Prognosis

106 works9,255 citations

What are the most-cited papers on Eternity Bioscience (United States)?

ScholarIQmost cited works

Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial

H. Wilke, Kei Muro, Eric Van Cutsem, Sang-Cheul Oh, G. Bodoky, Yasuhiro Shimada, Shuichi Hironaka, Naotoshi Sugimoto, Oleg Lipatov, Tae‐You Kim, David Cunningham, Philippe Rougier, Yoshito Komatsu, Jaffer A. Ajani, Michael Emig, Roberto Carlesi, David Ferry, Kumari Chandrawansa, Jonathan D. Schwartz, Atsushi Ohtsu

The Lancet Oncology. 20142,486 Citations

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Charles S. Fuchs, Jiří Tomášek, Cho Jae Yong, Filip Dumitru, Rodolfo Passalacqua, Chanchal Goswami, Howard Safran, Lucas Vieira dos Santos, Giuseppe Aprile, David Ferry, Bohuslav Melichar, Mustapha Tehfé, Э. Э. Топузов, John Zalcberg, Ian Chau, William Campbell, Choondal Devan Sivanandan, Joanna Pikiel, Minori Koshiji, Yanzhi Hsu, Astra M. Liepa, Ling Gao, Jonathan D. Schwartz, Josep Tabernero

The Lancet. 20132,207 CitationsOPEN ACCESS

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

Andrew X. Zhu, Joon Oh Park, Baek‐Yeol Ryoo, Chia-Jui Yen, Ronnie T. P. Poon, Davide Pastorelli, Jean-Frédéric Blanc, Hyun Cheol Chung, Ari David Baron, Túlio Pfiffer, Takuji Okusaka, Kateřina Kubáčková, Jörg Trojan, Javier Sastre, Ian Chau, Shao-Chun Chang, Paolo Abada, Ling Yang, Jonathan D. Schwartz, Masatoshi Kudo

The Lancet Oncology. 2015846 CitationsOPEN ACCESS

Phase II Trial Evaluating the Clinical and Biologic Effects of Bevacizumab in Unresectable Hepatocellular Carcinoma

Abby B. Siegel, E. Cohen, Allyson J. Ocean, Deborah Lehrer, Alec Goldenberg, Jennifer J. Knox, Helen Chen, Sean Clark-Garvey, Alan Weinberg, John Mandeli, Paul J. Christos, Madhu Mazumdar, E Popa, Robert S. Brown, Shahin Rafii, Jonathan D. Schwartz

Journal of Clinical Oncology. 2008510 CitationsOPEN ACCESS

Recurrence of hepatocellular carcinoma after liver transplant: Patterns and prognosis

Sasan Roayaie, Jonathan D. Schwartz, Max W. Sung, Sukru Emre, Charles M. Miller, Gabriel Gondolesi, Nancy Krieger, Myron Schwartz

Liver Transplantation. 2004464 Citations

How much of the research on Eternity Bioscience (United States) is open access?

ScholarIQopen access share

55%OPEN ACCESS

Gold

Green

27%

Hybrid

Bronze

18%

Closed

45%